PE20240110A1 - Variantes de anticuerpos felinos - Google Patents
Variantes de anticuerpos felinosInfo
- Publication number
- PE20240110A1 PE20240110A1 PE2023001243A PE2023001243A PE20240110A1 PE 20240110 A1 PE20240110 A1 PE 20240110A1 PE 2023001243 A PE2023001243 A PE 2023001243A PE 2023001243 A PE2023001243 A PE 2023001243A PE 20240110 A1 PE20240110 A1 PE 20240110A1
- Authority
- PE
- Peru
- Prior art keywords
- igg
- seq
- amino acids
- constant region
- constant domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084693P | 2020-09-29 | 2020-09-29 | |
| PCT/US2021/052579 WO2022072446A1 (en) | 2020-09-29 | 2021-09-29 | Feline antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240110A1 true PE20240110A1 (es) | 2024-01-22 |
Family
ID=78599139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001243A PE20240110A1 (es) | 2020-09-29 | 2021-09-29 | Variantes de anticuerpos felinos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12612455B2 (https=) |
| EP (2) | EP4221744A1 (https=) |
| JP (1) | JP2023542737A (https=) |
| KR (1) | KR20230091914A (https=) |
| CN (1) | CN116457369A (https=) |
| AR (1) | AR123645A1 (https=) |
| AU (1) | AU2021352395A1 (https=) |
| CA (1) | CA3195049A1 (https=) |
| CL (2) | CL2023000914A1 (https=) |
| CO (1) | CO2023004107A2 (https=) |
| EC (1) | ECSP23030307A (https=) |
| IL (1) | IL301414A (https=) |
| MX (1) | MX2023003694A (https=) |
| PE (1) | PE20240110A1 (https=) |
| TW (3) | TWI814094B (https=) |
| WO (1) | WO2022072446A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022072446A1 (en) | 2020-09-29 | 2022-04-07 | Zoetis Services Llc | Feline antibody variants |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| HRP20150279T1 (hr) * | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CA2875783C (en) | 2012-06-06 | 2018-12-11 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| US20210388053A1 (en) | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| JP7536294B2 (ja) * | 2018-12-05 | 2024-08-20 | 株式会社バイカ・セラピュティクス | 抗体のＦｃ領域改変体 |
| MX2022012793A (es) | 2020-04-17 | 2022-11-07 | Zoetis Services Llc | Variantes de anticuerpos felinos. |
| WO2022072446A1 (en) | 2020-09-29 | 2022-04-07 | Zoetis Services Llc | Feline antibody variants |
| KR20230121056A (ko) | 2020-12-18 | 2023-08-17 | 조에티스 서비시즈 엘엘씨 | 고양이 항체 불변 영역의 돌연변이 |
-
2021
- 2021-09-29 WO PCT/US2021/052579 patent/WO2022072446A1/en not_active Ceased
- 2021-09-29 AR ARP210102710A patent/AR123645A1/es unknown
- 2021-09-29 AU AU2021352395A patent/AU2021352395A1/en active Pending
- 2021-09-29 CA CA3195049A patent/CA3195049A1/en active Pending
- 2021-09-29 TW TW110136252A patent/TWI814094B/zh active
- 2021-09-29 PE PE2023001243A patent/PE20240110A1/es unknown
- 2021-09-29 US US18/246,725 patent/US12612455B2/en active Active
- 2021-09-29 TW TW114113296A patent/TW202545990A/zh unknown
- 2021-09-29 KR KR1020237014648A patent/KR20230091914A/ko active Pending
- 2021-09-29 EP EP21806456.6A patent/EP4221744A1/en not_active Withdrawn
- 2021-09-29 TW TW112132477A patent/TWI880316B/zh active
- 2021-09-29 MX MX2023003694A patent/MX2023003694A/es unknown
- 2021-09-29 EP EP25199779.7A patent/EP4711383A3/en active Pending
- 2021-09-29 JP JP2023519633A patent/JP2023542737A/ja active Pending
- 2021-09-29 IL IL301414A patent/IL301414A/en unknown
- 2021-09-29 CN CN202180077397.2A patent/CN116457369A/zh active Pending
-
2023
- 2023-03-29 CO CONC2023/0004107A patent/CO2023004107A2/es unknown
- 2023-03-29 CL CL2023000914A patent/CL2023000914A1/es unknown
- 2023-04-25 EC ECSENADI202330307A patent/ECSP23030307A/es unknown
-
2024
- 2024-03-18 CL CL2024000789A patent/CL2024000789A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12612455B2 (en) | 2026-04-28 |
| CO2023004107A2 (es) | 2023-04-27 |
| CN116457369A (zh) | 2023-07-18 |
| JP2023542737A (ja) | 2023-10-11 |
| US20230382986A1 (en) | 2023-11-30 |
| CL2023000914A1 (es) | 2023-10-20 |
| IL301414A (en) | 2023-05-01 |
| EP4221744A1 (en) | 2023-08-09 |
| TW202545990A (zh) | 2025-12-01 |
| MX2023003694A (es) | 2023-04-21 |
| TW202413413A (zh) | 2024-04-01 |
| KR20230091914A (ko) | 2023-06-23 |
| TWI814094B (zh) | 2023-09-01 |
| EP4711383A2 (en) | 2026-03-18 |
| TWI880316B (zh) | 2025-04-11 |
| CL2024000789A1 (es) | 2024-07-19 |
| WO2022072446A1 (en) | 2022-04-07 |
| AR123645A1 (es) | 2022-12-28 |
| EP4711383A3 (en) | 2026-04-29 |
| TW202222830A (zh) | 2022-06-16 |
| ECSP23030307A (es) | 2023-07-31 |
| CA3195049A1 (en) | 2022-04-07 |
| AU2021352395A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240110A1 (es) | Variantes de anticuerpos felinos | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| PE20230108A1 (es) | Variantes de anticuerpos caninos | |
| Thomson et al. | A simplified method for the efficient refolding and purification of recombinant human GM-CSF | |
| PE20211055A1 (es) | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas | |
| AR086982A1 (es) | Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i | |
| PE20191436A1 (es) | Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos | |
| BR112015000798A2 (pt) | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| PE20242297A1 (es) | Anticuerpo anti-ctla-4 | |
| PE20121530A1 (es) | Inmunoglobulinas con dominio variable dual | |
| JP2017512063A5 (https=) | ||
| PE20091382A1 (es) | Anticuerpos que se une a il-4 y/o a il-13 | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| AR080793A1 (es) | Anticuerpos biespecificos | |
| AR046833A1 (es) | Anticuerpos anti-interleuquina-10 | |
| JP2016526909A5 (https=) | ||
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| ES2173130T3 (es) | Metodo de fijacion de material al peptido beta-amiloide. | |
| JP2017509335A5 (https=) | ||
| FI3998285T3 (fi) | Cd38:aan ja pd-l1:een sitoutuvia molekyylejä | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| PE20200738A1 (es) | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl) |